Loading...
OTCM
EVFM
Market cap1mUSD
Jul 09, Last price  
0.01USD
1D
-1.06%
1Q
6.25%
IPO
-99.99%
Name

Evofem Biosciences Inc

Chart & Performance

D1W1MN
OTCM:EVFM chart
P/E
3.17
P/S
0.06
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
1,023.86%
Rev. gr., 5y
114.35%
Revenues
20m
+4.23%
100,0000000000446,0008,244,00016,837,00018,218,00019,363,00020,183,000
Net income
391k
P
-7,827,616-15,016,253-10,819,236-43,157,045-13,018,598-105,305,000-125,712,000-80,033,000-142,309,000-205,192,000-76,698,00052,979,000-8,860,000391,000
CFO
-2m
L-48.73%
-7,395,889-12,904,111-9,572,118-37,911,417-16,254,992-19,242,000-56,500,000-56,383,000-105,889,000-146,667,000-70,410,000-8,968,000-3,885,000-1,992,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
URL
https://www.evofem.com/
IPO date
Nov 20, 2014
Employees
35
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT